Compare CATY & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CATY | CDTX |
|---|---|---|
| Founded | 1962 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 2.8B |
| IPO Year | N/A | 2015 |
| Metric | CATY | CDTX |
|---|---|---|
| Price | $49.87 | $220.29 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 13 |
| Target Price | $50.80 | ★ $119.44 |
| AVG Volume (30 Days) | 370.5K | ★ 2.2M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 9.40 | N/A |
| EPS | ★ 4.33 | N/A |
| Revenue | ★ $711,617,000.00 | N/A |
| Revenue This Year | $18.83 | N/A |
| Revenue Next Year | $8.37 | N/A |
| P/E Ratio | $11.55 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.06 | $15.22 |
| 52 Week High | $52.43 | $221.20 |
| Indicator | CATY | CDTX |
|---|---|---|
| Relative Strength Index (RSI) | 63.12 | 88.29 |
| Support Level | $47.89 | $219.36 |
| Resistance Level | $50.45 | $221.20 |
| Average True Range (ATR) | 1.28 | 0.95 |
| MACD | 0.32 | -1.18 |
| Stochastic Oscillator | 90.41 | 82.06 |
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.